A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 157-162

  Kinon, Bruce J ^a   Lipkovich, Ilya ^a   Edwards, S Beth ^a   Adams, David H ^a   Ascher Svanum, Haya ^a   Siris, Samuel G ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; OLANZAPINE; PROLACTIN; TRIACYLGLYCEROL; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AKATHISIA; ARTICLE; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DOUBLE BLIND PROCEDURE; GLOBAL ASSESSMENT OF FUNCTIONING; HEADACHE; HUMAN; INCREASED APPETITE; INFLUENZA; INSOMNIA; MIGRAINE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEPRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PATIENT DROPOUTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES; WEIGHT GAIN;

EID: 33646681652     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000204137.82298.06     Document Type: Article

References (16)

1. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14(3):229-234.
2. Siris SG. Depression and schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000;157(9):1379- 1389.
3. Johnson DA. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry. 1988;152:320-323.
4. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999;25(1):157-171.
5. Siris SG. Suicide in schizophrenia. J Psychopharmacol. 2001;15(2):127-135.
6. Tollefson GD, Sanger TM, Beasley CM, et al. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptom accompanying schizophrenia. Biol Psychiatry. 1998;43(11):803-810.
7. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry. 1999;46(3):365-373.
8. Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res. 1997;4:159-177.
9. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology. 1998;140(2):173-184.
10. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(10):1837-1847.
11. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162(10):1879-1887.
12. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for Schizophrenics. Schizophr Res. 1994;11(3):239-244.
13. Mallinckrodt CH, Sanger TM, Dube S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53(8):754-760.
14. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
15. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
16. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349.